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AbstrACt
Evidence has shown that metabolic disorders are common in tumor cells, leading to increased oxidative 
stress. The increase in the production of reactive oxygen species (ROS) associated with low antioxi-
dant activity has been related to several types of cancer. Selenium, an antioxidant micronutrient, may 
function as an antimutagenic agent, preventing the malignant transformation of normal cells. A review 
of the literature was conducted based on a survey of articles published between 2000 and 2009 in 
the PubMed database; 39 articles that analyzed the relationship between cancer, oxidative stress and 
selenium supplementation were selected. The protective effect of this mineral is especially associated 
with its presence in the glutathione peroxidase and thioredoxin reductase, enzymes that are known 
to protect DNA and other cellular components against oxidative damage caused by ROS. Several 
studies have shown reduced expression of these enzymes in various types of cancer, especially when 
associated with low intake of selenium, which may increase the damage. Selenium supplementation 
appears to reduce the risk of some types of cancer by reducing oxidative stress and DNA damage. 
However, further studies are needed to clarify the adequate dose of selenium for each situation (sex, 
geographic location, and type of cancer). 
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Review Article
introduction
Evidence has shown that metabolic disorders are common 
in tumor cells, leading to increased oxidative stress. According 
to Cutler,1 oxidative stress is defined as an imbalance between 
antioxidants and reactive oxygen species (ROS) in favor of 
the latter . ROS, which include free radicals, are continuously 
produced in the body and play an important physiological role 
at low concentrations. 
At high concentrations, due to their high reactivity, ROS 
can cause irreversible damage through oxidative changes in 
lipids, proteins, and DNA. It is suspected that changes in these 
structures are related to the development of several human 
diseases, including cancer.1
To limit the harmful effects of ROS, a high-performance 
antioxidant system composed of an enzymatic and a nonen-
zymatic system may interact with ROS by regulating their 
production, reducing it to physiological limits. If this antioxidant 
defense is surpassed by the production of ROS or not sufficiently 
provided through diet or supplementation, oxidative stress can 
occur.1 
Selenium (Se), a micronutrient with an important antioxi-
dant action, functions as an antimutagenic agent, preventing 
the malignant transformation of normal cells. This protective 
effect of selenium was primarily associated with its presence in 
the glutathione peroxidase and thioredoxin reductase, enzymes 
that are known to protect DNA and other cellular components 
from oxidative damage.2,3 
Some mechanisms have been suggested to explain the 
anticarcinogenic effects of selenium: the action of seleno-
enzymes in reducing DNA damage, oxidative stress reduc-
tion, reduced inflammation, detoxification, improved immune 
response, increased tumor suppressor protein p53, inactivation 
of protein kinase C, alteration in DNA methylation, cell cycle 
arrest, induction of apoptosis of cancer cells, and inhibition of 
angiogenesis.3-6 
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This study aimed to gather information about the rela-
tionship between cancer, oxidative stress and supplementation 
with selenium. For this purpose, we provided an overview 
of selenium and the major selenoproteins, their response 
in the face of certain types of cancer, and issues related to 
supplementation.
Methods
A review of the literature was conducted based on a survey 
of articles published between 2000 and 2009 in the PubMed 
database, using “selenium” and “cancer” as search descrip-
tors. Our search detected 1263 articles; of these, we selected 
those written in English, with animals and humans, and that 
investigated the antioxidant action of selenium and its supple-
mentation in cancer, totaling 39 articles. 
Selenoproteins and their actions
Selenium is a trace element essential for the normal function 
of the body and can be present in inorganic form, metallic form 
(Se0) or oxyanions, such as selenite (SeO(OH)2) and selenate 
(SeO2(OH)2), and also in organic forms, such as selenocysteine 
(SeCys) and selenomethionine (SeMet), analogs of sulfur-
containing amino acids cysteine and methionine, respectively.7 
Once selenium compounds are recognized as selenium 
species, they are transformed into selenide, a common inter-
mediate metabolite, and then used for the synthesis of seleno-
proteins (selenoenzymes) or excreted after being methylated 
stepwise. SeMet is an exceptional selenium compound, since, 
when recognized as a selenium species, it can be transformed 
into SeCys through the trans-selenation pathway and then 
lysed by β-lyase ou y-lyase to selenide. However, at the same 
time, SeMet can be used for the synthesis of proteins without 
the body distinguishing between SeMet and methionine,7 by 
methionine-tRNA.8
SeCys is present as an amino acid residue in selenopro-
teins in plants and animals, which is incorporated into amino 
acid sequences of selenoproteins by a specific codon to SeCys 
residue. SeMet is present in the form of SeMet residue in 
general proteins. Thus, proteins containing selenium in the 
form of SeCys are called selenoproteins, while those containing 
selenium in the form of SeMet are simply called selenium-
containing proteins.7
Currently, five human glutathione peroxidase (GPx) isoen-
zymes containing SeCys are known, exhibiting tissue-specific 
expressions and different substrate specificities.9 They are: 
GPx-1, found in the cytosol; GPx-2, an enzyme specific to the 
gastrointestinal tract; GPx-3, secreted into plasma proteins; 
GPx-4, acts on oxidized lipids, being called phospholipid hydro-
peroxide GPx; and snGPx, a specific sperm nuclei enzyme.10 
All these GPx isoenzymes have in common a catalytic triad 
within their active center, consisting of SeCys, glutamine, and 
tryptophan residues.11 Their antioxidant capacity is due to a 
reduction in hydrogen peroxidase, organic hydroperoxide and 
phospholipid hydroperoxide (only GPx-4), usually requiring two 
glutathione equivalents as a cosubstrate.12
In addition to GPx, the thioredoxin reductase (TrxR) sele-
noenzyme family is also capable of degrading hydroperoxides, 
as demonstrated by the reduction in hydrogen peroxide and 
lipid hydroperoxide by human placenta TrxR.13  TrxR catalyzes 
the reduction of thioredoxin primarily, but in humans it can 
also reduce other substrates, such as vitamin C. Thioredoxin 
catalyzes the reduction of protein disulfides and is involved in 
numerous vital processes, such as DNA synthesis and regula-
tion of apoptosis.14 All three human TrxR isoenzymes contain 
an essential SeCys residue in their C-terminal: cytosolic TrxR-1; 
mitochondrial TrxR-2; and TrxR-3, a testis-specific glutathione/
thioredoxin reductase.15,16
Regardless of the direct reduction of hydroperoxides, TrxRs 
are involved in the protection against ROS by controlling the 
redox state of thioredoxin.17 Therefore, reduced thioredoxin may 
serve as an electron donor for numerous intra and extracellular 
antioxidant enzymes: thioredoxin reduces several oxidized 
peroxiredoxins, a large family of cytoprotective enzymes that 
degrade hydroperoxide and peroxynitrite, thereby restoring their 
enzymatic activity.18 Methionine sulfoxide reductase, which 
repairs oxidized methionine residues in proteins,19 requires 
thioredoxin for its subsequent reduction20.
In the extracellular environment, where glutathione levels 
are usually low compared to the intracellular compartment,21 
thioredoxin can replace glutathione as an electron donor for 
redox reactions.10 Plasma GPx (GPx-3), the most important 
selenoenzyme in the detoxification of ROS in human plasma, 
catalyzes the reduction of extracellular hydrogen peroxide and 
lipid hydroperoxide and accepts both thioredoxin and gluta-
thione as a reduction cosubstrate.22
Selenoprotein P (SeP), the second selenoprotein to be disco-
vered, was designated “P” for being found in blood plasma. 
Incomplete isoforms of this protein have been found and may 
contain from 1 to 17 SeCys, depending on the animal species. 
SeP is expressed in many tissues, but it is produced primarily 
in the liver and secreted into the plasma. SeP is the largest 
form of selenium in plasma and is involved in its transport.23,24 
There are indications that SeP also acts as an antioxidant in the 
extracellular space. SeP is located in the endothelium, bound to 
heparin and associated with carbohydrates.24 SeP can reduce 
peroxynitrite and phospholipid hydroperoxide,25,26 can form 
mercury- and cadmium-selenium complexes,27 and can also 
stimulate the survival of cultured central neurons.28
There is experimental evidence for an additional role of 
SeP as a ROS detoxification enzyme. Two enzymatic activities 
of SeP were demonstrated in vitro: SeP reduced phospholipid 
hydroperoxides using glutathione or thioredoxin as a cosubs-
trate26,29  and protected plasma proteins against oxidation and 
nitration induced by peroxynitrite or peroxidation of low density 
lipoproteins (LDL).25,30 In addition, SeP was also shown to 
protect human astrocytes and endothelial cells from oxidative 
damage.31,32
Selenoproteins and cancer prevention
Since the genotoxic damage caused by the accumulation 
of oxidative modifications in DNA bases and DNA single- or 
double-strand breaks are outstanding features in the develop-
ment of many forms of cancer, selenium has been suggested 
to exert its anticarcinogenic function through ROS detoxifi-
cation selenoenzymes. In humans, indirect evidence for the 
Almondes KGs et Al.
486 Rev Assoc Med Bras 2010; 56(4): 484-8
connection between cancer risk and a pattern of altered expres-
sion of selenoproteins has been provided by genetic data such 
as proliferation of cancer tissue expressions.9
An allelic variant of GPx-1 gene, with high prevalence among 
Caucasians caused by a single nucleotide polymorphism at 
codon 198, was associated with increased risk of lung cancer.33 
In addition, loss of one GPx-1 allele (loss of heterozygosity) is 
frequently observed in DNA from tissues with lung cancer.34 A 
significant reduction in the regulation of SeP mRNA levels was 
found in colorectal and prostate cancer tissues.35,36 DDuring 
the progression of colorectal cancer, GPx-1, GPx-3 and SeP 
expressions decrease, whereas GPx-2 expression increases.37 
TrxR-1 overexpression is also characteristic of several forms 
of cancer.38
Studies in animals and cell cultures have corroborated the 
anticarcinogenic role of several selenoenzymes. Accelerated 
carcinogenesis of the prostate was observed in transgenic 
mice displaying impaired selenoprotein biosynthesis,39 and 
selenium status was shown to be inversely correlated with the 
extent of DNA damage in the prostate of elderly beagle dogs.40 
GPx-1 overexpression as well as selenium supplementation 
protected mammalian cells against ultraviolet (UV)-induced 
DNA damage.41 GPx-4 overexpression impeded solid tumor 
growth of tumorigenic L929 fibrosarcoma cells and increased 
the sensitivity of tumorigenic B16BL6 melanoma cells to angio-
destructive therapy.42
The anticarcinogenic role of GPx-1, GPx-4 and SeP appears 
to rely mostly on their function as hydroperoxide degradation 
enzymes. In contrast, GPx-2 and TrxR-1 certainly act as a 
“double-edged sword” exhibiting anti and procarcinogenic 
properties. This dual role of GPx-2 has been recently highli-
ghted by an approach using small interfering RNA (siRNA) to 
knock down GPx-2 expression, which inhibited migration and 
invasion of human adenocarcinoma cells, but supported tumor 
cell growth in mice.43
The same experimental approach was used before to 
evaluate the role of TrxR-1 in carcinogenesis: siRNA-induced 
TrxR-1 knockdown in mouse lung carcinoma cells caused a 
reversal in tumor phenotype and inhibition of tumor growth 
and metastasis.44 On the other hand, TrxR-1 assists in cancer 
prevention by degrading hydroperoxides,13 supplying reduced 
thioredoxin to the reduction of oxidized peroxiredoxins,18 and 
controlling the redox state of many transcription factors.45,46
Other selenocompounds affect the signal transduction 
in tumor cells, as demonstrated by methylseleninic acid 
(MSeA). In fibrosarcoma cells, MSeA inhibited the activation of 
matrix metalloproteinase-2 (MMP-2) by promoting 12-O-tetra-
decanoylphorbol-13-acetate (PMA) in the tumor through 
the  suppression of nuclear factor-kappa B (NF-ƙB) signal 
pathway.47 Protein kinase C (PKC), which is activated by PMA 
and involved in carcinogenesis, was shown to be inactivated 
by locally generated MSeA.48
PKC reduction is bound to lipid hydroperoxides by the 
MSeA-generated selenocompound methylselenol, which inac-
tivates PKC through the specific oxidation of sulfhydryls in its 
catalytic domain. The redox modification of PKC can be reversed 
by TrxR-1 using thioredoxin as a reduction cosubstrate. This 
sophisticated model can explain the interrelationship between 
the actions of selenocompounds and TrxR-1 selenoenzyme in 
controlling PKC activity, and may eventually contribute to a 
better understanding of the complex anti- and pro-oxidative 
effect of selenium in cancer prevention.48
Selenium supplementation as a chemopreventive agent 
Selenium is an essential nutrient with anticarcinogenic 
potential, particularly when supplemented. The main forms 
of selenium supplement are SeMet and SeCys. In low doses, 
selenium functions as an essential component of SeCys in 
various specific selenoproteins and promotes cell proliferation, 
important for immune response. In high but nontoxic doses, 
selenium may reduce the risk of cancer by blocking tumor cell 
cycle, stimulating apoptosis, and inhibiting tumor cell migration 
and invasion.49
In a review conducted by Navarro-Alcarón et al.,50 fthe 
authors found 14 studies showing significantly low selenium 
levels in cancer patients compared to controls. Low serum 
selenium concentration was also correlated with increased 
risk of cancer. In addition, Czeczot et al.51 found a reduction in 
GPx activity in hepatocellular carcinoma compared to adjacent 
normal tissue. This reduction may cause the intensification of 
lipid peroxidation and the increased level of final products of 
peroxidation, such as malondialdehyde (MDA). Concomitantly, 
increased levels of MDA in cancer tissues were also found. 
Therefore, some researchers recommend selenium in nutritional 
cancer prophylaxis at doses of 50 to 100 μg Se/day. Selenium 
has also been recommended as an adjuvant to chemotherapy 
in the treatment of cancer at doses of 200 μg Se/day.52, 53 
The first double-blind study using selenium as a chemo-
preventive agent, Nutritional Prevention of Cancer (NPC), was 
published in 1996 by Clark et al.54 A total of 1312 individuals 
of both sexes were studied and no significant effects were 
observed in the incidence of nonmelanoma skin cancer after 
daily supplementation with 200 μg Se/day. Using data from 
this same study, 457 men who received such selenium supple-
mentation were compared to 470 men receiving placebo (a 
seven-year follow-up study), and a significantly lower incidence 
of prostate, lung and colorectal cancer was observed among 
those supplemented.55,56
More recent data on cancer-related selenium supplementa-
tion have been observed. In a randomized double-blind study 
with individuals at high risk of developing prostate cancer, 
patients received selenium supplementation for six months. 
After this period, TrxR activity of the group increased by 80%. 
However, GPx activity was not affected.57
Observing the effect of selenium supplementation on GPx 
expression in different lung cancer cell lines (H460, H1703, 
H1944), Romanowska et al.58 found that the full expression 
of GPx-1 and GPx-4 in these cells requires the presence of at 
least 100 nM of selenium. The impact of selenium supple-
mentation varied according to the type of lung cancer cell and 
the type of GPx. In two cancer cell lines, selenium deficiency 
reduced GPx-1 levels, but had no effect on GPx-4. In a third 
cell line, GPx-1 showed minimal expression regardless of 
selenium concentration, but GPx-4 was highly responsive to 
supplementation. 
Studies in animals have shown a protective effect of various 
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forms of selenium against many types of cancer, including liver, 
skin, mammary, and colon cancer. In particular, the deve-
lopment of 7,12-dimethybenzanthracene (DMBA)-induced 
mammary cancer and UV-induced skin cancer was signifi-
cantly reduced in animals receiving selenium.59,60. In a rat 
model, selenium supplementation also significantly reduced the 
carcinogenic process in chemically induced liver cancer when 
administered during the promotion and progression phases.61
In a review conducted by Bardia et al.,62 the authors 
concluded that selenium supplementation appears to reduce 
the risk of cancer, especially among men, but the results should 
be interpreted with caution due to variations in selenium 
concentrations according to sex and geographic location. Men 
showed higher serum selenium levels than women after supple-
mentation, and most studies were conducted in areas where 
individuals were likely to be nutritionally deficient in selenium. 
A larger number of epidemiological studies using interven-
tional selenium supplementation in the treatment of cancer 
might provide further data to better define the benefits and risks 
of different types and doses of selenium to be used.14
Moreover, studies evaluating the importance of selenium 
in cancer treatment in humans refer more to the role of this 
mineral in prostate and colorectal cancer63-69 and less to its role 
in cases of bladder cancer.70,71
conclusion
Low selenium concentrations, as well as a reduced expres-
sion of selenoproteins, are associated with a high risk of cancer. 
Studies in animals and humans have shown that selenium 
has a protective effect in the prevention and treatment of 
cancer, highlighting that supplementation with this mineral 
has yielded good results in reducing the carcinogenic process. 
However, further studies are necessary to elucidate the effect 
of selenoproteins on various types of cancer, focusing not only 
on prostate and colorectal tumors, which are the most cited in 
the literature. Furthermore, the adequate dose of selenium for 
each situation (sex, geographic location, and type of cancer) 
should be investigated. 
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